DiaMedica Therapeutics initiated with a Buy at. Dougherty analyst Kyle Bauser initiated DiaMedica Therapeutics with a Buy rating and $8 price target, citing what he calls a “large body of clinical evidence” supporting the benefit of KLK1 to treat Chronic Kidney Disease and acute ischemic stroke. He notes that data readouts are due later this year from company’s synthetic version of KLK1.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.